Work

Should toxicity be taken into account in determining chemotherapy backbone in HER2-positive (HER2+) early breast cancer (eBC)?

Year: 2025

Type: article

Study design: Observational Study

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e12628

Authors: Beatriz Alonso de Castro, Cristina Reboredo Rendo, Lourdes Calvo, Eva Perez Lopez, Silvia Antolín Novoa

Institutions: Complexo Hospitalario Universitario A Coruña, GEICAM – Spanish Breast Cancer Group

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410814638

FWCI:

Cites:

Cited by:

Related to: 10